Journal of Clinical Endocrinology & Metabolism, Vol 80, 1194-1202, Copyright © 1995 by Endocrine Society

ARTICLES

Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus

R Bouillon, M Bex, E Van Herck, J Laureys, L Dooms, E Lesaffre and E Ravussin
Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Gasthuisberg, Katholieke Universiteit Leuven, Belgium.

The osteoblast function was evaluated in normal and diabetic children and adults by measurements of the serum concentration of the carboxy- terminal extension peptide of procollagen (PICP), total and skeletal alkaline phosphatase (ALP), and osteocalcin. Moreover, the osteoblast- stimulating growth factor, insulin-like growth factor I (IGF-I), was measured in the same samples. In normal children (n = 420; age, 5-20 yr), a marked pubertal increase of serum IGF-I (peak values at age 14- 16 yr in both sexes), osteocalcin, and total and skeletal ALP (peak values earlier in girls than in boys) and a small increase in PICP were observed. All osteoblast markers and IGF-I were markedly lower in normal adults (n = 229; age, 21-69 yr) than in children. All osteoblast parameters showed a high degree of correlation (P < 0.001) with each other. In adolescents (n = 104) treated for insulin-dependent diabetes mellitus (IDDM), serum IGF-I (-19%), osteocalcin (-28%), and skeletal ALP (-28%) were markedly decreased, whereas total ALP was significantly increased (29%), and serum PICP remained normal. In adult IDDM (n = 125), both serum IGF-I (-41%) and osteocalcin (-24%) were decreased, but skeletal ALP and PICP remained normal. A similar abnormality in serum IGF-I and osteocalcin was observed in white (n = 61) and Pima Indian (n = 16) non-IDDM patients. The concentration of skeletal ALP was highly significantly correlated (r > or = 0.9) with total ALP in both normal and diabetic subjects, but the slope of the regression was significantly different, indicating the presence of other, probably intestinal, ALP in all types of diabetes. In conclusion, the osteoblast function is significantly decreased in diabetic patients, which can best be characterized as a maturation defect, since the early osteoblast marker, PICP, remained normal in all types of diabetes, whereas a later marker, skeletal ALP, is frankly abnormal only in diabetic children. The most mature osteoblast marker, osteocalcin, is decreased in all types of diabetes irrespective of age.

This article has been cited by other articles:

				A. G. Pittas, S. S. Harris, M. Eliades, P. Stark, and B. Dawson-Hughes Association between Serum Osteocalcin and Markers of Metabolic Phenotype J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 827 - 832. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, M. Izquierdo, F. Ortega, E. Gorostiaga, J. Gomez-Ambrosi, J. M. Moreno-Navarrete, G. Fruhbeck, C. Martinez, F. Idoate, J. Salvador, et al. The Relationship of Serum Osteocalcin Concentration to Insulin Secretion, Sensitivity, and Disposal with Hypocaloric Diet and Resistance Training J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 237 - 245. [Abstract] [Full Text] [PDF]

				H.-F. Chen, C.-A. Ho, and C.-Y. Li Increased Risks of Hip Fracture in Diabetic Patients of Taiwan: A population-based study Diabetes Care, January 1, 2008; 31(1): 75 - 80. [Abstract] [Full Text] [PDF]

				S. Botolin and L. R. McCabe Bone Loss and Increased Bone Adiposity in Spontaneous and Pharmacologically Induced Diabetic Mice Endocrinology, January 1, 2007; 148(1): 198 - 205. [Abstract] [Full Text] [PDF]

				R. Irwin, H. V. Lin, K. J. Motyl, and L. R. McCabe Normal Bone Density Obtained in the Absence of Insulin Receptor Expression in Bone Endocrinology, December 1, 2006; 147(12): 5760 - 5767. [Abstract] [Full Text] [PDF]

				J. Leger, D. Marinovic, C. Alberti, S. Dorgeret, D. Chevenne, C. L. Marchal, N. Tubiana-Rufi, G. Sebag, and P. Czernichow Lower Bone Mineral Content in Children with Type 1 Diabetes Mellitus Is Linked to Female Sex, Low Insulin-Like Growth Factor Type I Levels, and High Insulin Requirement J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3947 - 3953. [Abstract] [Full Text] [PDF]

				S. Bechtold, I. Dirlenbach, K. Raile, V. Noelle, W. Bonfig, and H. P. Schwarz Early Manifestation of Type 1 Diabetes in Children Is a Risk Factor for Changed Bone Geometry: Data Using Peripheral Quantitative Computed Tomography Pediatrics, September 1, 2006; 118(3): e627 - e634. [Abstract] [Full Text] [PDF]

				S. Botolin, M.-C. Faugere, H. Malluche, M. Orth, R. Meyer, and L. R. McCabe Increased Bone Adiposity and Peroxisomal Proliferator-Activated Receptor-{gamma}2 Expression in Type I Diabetic Mice Endocrinology, August 1, 2005; 146(8): 3622 - 3631. [Abstract] [Full Text] [PDF]

				A. Afghani, M. L. Cruz, and M. I. Goran Impaired Glucose Tolerance and Bone Mineral Content in Overweight Latino Children With a Family History of Type 2 Diabetes Diabetes Care, February 1, 2005; 28(2): 372 - 378. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				T. T. Brown, M. D. Ruppe, R. Kassner, P. Kumar, T. Kehoe, A. S. Dobs, and J. Timpone Reduced Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients and Its Association with Increased Central Adiposity and Postload Hyperglycemia J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1200 - 1206. [Abstract] [Full Text] [PDF]

				R. B. Santana, L. Xu, H. B. Chase, S. Amar, D. T. Graves, and P. C. Trackman A Role for Advanced Glycation End Products in Diminished Bone Healing in Type 1 Diabetes Diabetes, June 1, 2003; 52(6): 1502 - 1510. [Abstract] [Full Text] [PDF]

				J. Verhaeghe, A. Pintiaux, E. van Herck, G. Hennen, J.-M. Foidart, and A. Igout Placental GH, IGF-I, IGF-Binding Protein-1, and Leptin during a Glucose Challenge Test in Pregnant Women: Relation with Maternal Body Weight, Glucose Tolerance, and Birth Weight J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2875 - 2882. [Abstract] [Full Text] [PDF]

				Y. Wada, Y. Nakamura, and H. Koshiyama Lack of Positive Correlation Between Statin Use and Bone Mineral Density in Japanese Subjects With Type 2 Diabetes Arch Intern Med, October 9, 2000; 160(18): 2865 - 2865. [Full Text] [PDF]

				G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R. C. Baxter, J. D. Veldhuis, C. Y. Bowers, and R. Bouillon Reactivation of Pituitary Hormone Release and Metabolic Improvement by Infusion of Growth Hormone-Releasing Peptide and Thyrotropin-Releasing Hormone in Patients with Protracted Critical Illness J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1311 - 1323. [Abstract] [Full Text]

				R. Okazaki, Y. Totsuka, K. Hamano, M. Ajima, M. Miura, Y. Hirota, K. Hata, S. Fukumoto, and T. Matsumoto Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2915 - 2920. [Abstract] [Full Text] [PDF]

				P. M. Crofton, J. C. Wade, M. R. H. Taylor, and C. V. Holland Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren Clin. Chem., September 1, 1997; 43(9): 1577 - 1581. [Abstract] [Full Text] [PDF]